TCGA-CV-7418-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.180136986
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.350
- OXIDATIVE_PHOSPHORYLATION+0.340
- SPERMATOGENESIS+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.240
- MYC_TARGETS_V2+0.240
- MYC_TARGETS_V1+0.220
- MTORC1_SIGNALING+0.190
- HEDGEHOG_SIGNALING+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- INTERFERON_ALPHA_RESPONSE-0.470
- APICAL_JUNCTION-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- ANGIOGENESIS-0.340
- INFLAMMATORY_RESPONSE-0.340
- ALLOGRAFT_REJECTION-0.330
- NOTCH_SIGNALING-0.320
- TGF_BETA_SIGNALING-0.300
- TNFA_SIGNALING_VIA_NFKB-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15069607 | — | — | 0.880 |
| 2 | TCGA-86-A4D0-01A-11R-A24H-07 | — | cohortA3 | 0.872 |
| 3 | C3N-01017 | — | cohortSQ2 | 0.870 |
| 4 | SRR25043617 | — | — | 0.848 |
| 5 | TCGA-63-A5MB-01A-11R-A26W-07 | — | cohortSQ2 | 0.847 |
| 6 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.842 |
| 7 | TCGA-YC-A9TC-01A-22R-A39I-07 | — | — | 0.841 |
| 8 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.832 |
| 9 | TCGA-39-5027-01A-21R-1820-07 | — | cohortSQ2 | 0.831 |
| 10 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |